New booster aims to shield the vulnerable from COVID-19
NCT ID NCT05303402
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested an extra dose of the HIPRA COVID-19 vaccine in 241 adults with conditions like HIV, kidney disease, or autoimmune disorders that weaken the immune system. The goal was to see if the booster raises antibody levels against virus variants and remains safe. Researchers measured immune responses before and 14 days after the shot, with follow-ups up to a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HIPRA COVID-19 vaccine (PHH-1V)
What this could lead to
If successful, this could provide a safe and effective booster option for people with weakened immune systems, helping them stay protected against COVID-19 variants.
What could go wrong
This is a mid-stage trial with only 241 participants and no comparison group, so results may not apply to everyone. The vaccine may not work as well in all immunosuppressed individuals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ankara University Medical Faculty Hospitals
Ankara, Ankara, 06620, Turkey (Türkiye)
-
Hacettepe University Medical Faculty Hospitals
Ankara, Ankara, 06230, Turkey (Türkiye)
-
Hospital Clínic de Barcelona
Barcelona, Barcelona, 08036, Spain
-
Hospital Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
-
Hospital Josep Trueta
Girona, Girona, 17001, Spain
-
Koc University Hospital
Istanbul, Istanbul, 34010, Turkey (Türkiye)